OCUGEN, INC. Debt Securities, Available-for-sale, Amortized Cost, Current
OCUGEN, INC. (OCGN) had Debt Securities, Available-for-sale, Amortized Cost, Current of $8.46 million as of 2023-03-31, per its 10-Q filed 2023-05-05.
Discontinued › Notes
us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent · last filed 2024-04-16
- 2023-03-31: Debt Securities, Available-for-sale, Amortized Cost, Current $8.46M.
- 2022-12-31: Debt Securities, Available-for-sale, Amortized Cost, Current $13.37M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost, Current |
|---|---|
| 2023-03-31 | $8.46M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $13.37M 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |